Today, Investors Sell Shares of Edwards Lifesciences Corp (EW) on Strength After Insider Selling

Today, Investors Sell Shares of Edwards Lifesciences Corp (EW) on Strength After Insider Selling

Investors sold shares of Edwards Lifesciences Corp (NYSE:EW) on strength during trading hours on Thursday after an insider sold shares in the company. $39.64 million flowed into the stock on the tick-up and $55.03 million flowed out of the stock on the tick-down, for a money net flow of $15.39 million out of the stock. Of all companies tracked, Edwards Lifesciences Corp had the 0th highest net out-flow for the day. Edwards Lifesciences Corp traded up $1.82 for the day and closed at $86.86Specifically, VP Donald E. Bobo, Jr. sold 18,000 shares of the stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $115.78, for a total transaction of $2,084,040.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael A. Mussallem sold 49,100 shares of the stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $92.77, for a total transaction of $4,555,007.00. The disclosure for this sale can be found here. 2.37% of the stock is currently owned by insiders.

A number of equities research analysts have issued reports on the stock. Leerink Swann reiterated a “buy” rating on shares of Edwards Lifesciences Corp in a report on Friday, August 19th. Morgan Stanley reiterated a “buy” rating and set a $140.00 target price on shares of Edwards Lifesciences Corp in a report on Friday, August 19th. Credit Suisse Group AG set a $116.00 target price on shares of Edwards Lifesciences Corp and gave the stock a “buy” rating in a report on Thursday, August 18th. Evercore ISI reiterated a “hold” rating and set a $115.00 target price on shares of Edwards Lifesciences Corp in a report on Friday, August 19th. Finally, Canaccord Genuity restated a “buy” rating and issued a $140.00 price objective on shares of Edwards Lifesciences Corp in a report on Thursday, August 18th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the stock. Edwards Lifesciences Corp has an average rating of “Buy” and an average price target of $117.68.

The company has a market capitalization of $18.35 billion, a PE ratio of 33.91 and a beta of 0.71. The company’s 50 day moving average is $100.51 and its 200 day moving average is $106.69.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 25th. The medical research company reported $0.68 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.68. The firm had revenue of $739.40 million for the quarter, compared to analysts’ expectations of $749.14 million. Edwards Lifesciences Corp had a net margin of 19.24% and a return on equity of 24.32%. The firm’s quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.54 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Corp will post $2.88 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of EW. Ameriprise Financial Inc. boosted its stake in Edwards Lifesciences Corp by 62.3% in the second quarter. Ameriprise Financial Inc. now owns 4,253,976 shares of the medical research company’s stock valued at $424,200,000 after buying an additional 1,632,567 shares in the last quarter. American Century Companies Inc. boosted its stake in Edwards Lifesciences Corp by 83.1% in the second quarter. American Century Companies Inc. now owns 1,423,750 shares of the medical research company’s stock valued at $141,991,000 after buying an additional 646,142 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in Edwards Lifesciences Corp during the second quarter valued at about $58,912,000. 1832 Asset Management L.P. bought a new stake in Edwards Lifesciences Corp during the third quarter valued at about $67,325,000. Finally, Capital Fund Management S.A. boosted its stake in Edwards Lifesciences Corp by 10,543.8% in the second quarter. Capital Fund Management S.A. now owns 473,012 shares of the medical research company’s stock valued at $47,173,000 after buying an additional 468,568 shares in the last quarter. 83.99% of the stock is currently owned by hedge funds and other institutional investors.

Related posts

Leave a Comment